

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

LISTING OF CLAIMS:

Claims 1 to 48 (Canceled)

49. (Previously presented) A vaccine comprising a recombinant attenuated respiratory syncytial virus, the genome of which contains the reverse complement of an mRNA coding sequence operatively linked to a polymerase binding site of a respiratory syncytial virus, and a pharmaceutically acceptable carrier, wherein the genome comprises a genetic alteration wherein the genetic alteration is a deletion of the NS1 gene.

Claims 50 to 52 (Canceled)

53. (Currently amended) The vaccine of claim 49, wherein the virus is capable ~~to go through only one round of replication~~ of going through only one round of replication in the host.

Claims 54 to 56 (Canceled)

57. (Previously presented) An immunogenic composition comprising a recombinant attenuated respiratory syncytial virus, the genome of which contains the reverse complement of an mRNA coding sequence operatively linked to a polymerase binding site of a respiratory syncytial virus, and a pharmaceutically acceptable carrier, wherein the genome comprises a genetic alteration wherein the genetic alteration is a deletion of the NS1 gene.

Claims 58 to 68 (Canceled)

69. (Currently amended) The immunogenic composition of claim 57 ~~[[or 58]], wherein the virus is capable to go through only one round of replication~~ of going through only one round of replication in the host.

70. (Currently amended) A vaccine comprising the immunogenic composition of claim 57, ~~58, 61, 62, 63, 66, 67, or 68~~.

Claims 71 and 72 (Canceled)

73. (Previously presented) A pharmaceutical composition comprising (1) a recombinant attenuated respiratory syncytial virus, the genome of which contains the reverse complement of an mRNA coding sequence operatively linked to a polymerase binding site of a respiratory syncytial virus, and a pharmaceutically acceptable carrier, wherein the genome comprises a genetic alteration wherein the genetic alteration is a deletion of the NS1 gene; and (2) a pharmaceutically acceptable carrier.

Claims 74 to 82 (Canceled)

83. (Currently amended) The pharmaceutical composition of claim 73 [[or 74]], wherein the virus is capable ~~to go through only one round of replication~~ of going through only one round of replication in the host.